Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome

Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer.

(2017) G. Kristensen et al.   JOURNAL OF CLINICAL ONCOLOGY

The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt

(2011) Patrick Royston et al.   STATISTICS IN MEDICINE

Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial

(2010) Martin E Gore et al.   LANCET

Lymphadenectomy in endometrial cancer – Authors' reply

(2009) Henry Kitchener et al.   LANCET

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pseudo-observations in survival analysis

(2009) Per Kragh Andersen et al.   STATISTICAL METHODS IN MEDICAL RESEARCH

The estimation of average hazard ratios by weighted Cox regression

(2009) Michael Schemper et al.   STATISTICS IN MEDICINE

Visualizing Length of Survival in Time-to-Event Studies: A Complement to Kaplan Meier Plots

(2008) P. Royston et al.   JNCI-Journal of the National Cancer Institute